Sidra Medicine Establishes Autism-Friendly Hospital Initiative
Creating a calmer and more accessible healthcare environment for children with autism spectrum disorder 1 April 2024, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has established a Autism-Friendly Hospital Initiative (AFHI), designed to create a more inclusive and supportive healthcare environment for children with Autism Spectrum Disorder (ASD). The innovative program addresses the unique challenges faced by children with ASD during medical visits, including sensory overload, communication difficulties, and anxiety, all of which can hinder optimal care. Dr. Finza Latif, Senior Attending Physician and Fellowship Program Director at Sidra Medicine said: “We introduced this initiative to address the challenges children with ASD face in healthcare. Between 2023 and 2024, we saw a 14 percent increase in admissions, highlighting the growing need for tailored support. Sensory overload, communication barriers, and anxiety can make medical visits overwhelming. By creating an autism-friendly environment and offering specialized support, we aim to reduce these barriers and ensure every child receives the care they need”. Key Components of the AFHI Program: Prof. Muhammad Waqar Azeem, Chair of Department of Psychiatry at Sidra Medicine said: “We are very proud of the initiatives we have in place to make our services more accessible for children with ASD. From designated blood draw days with trained phlebotomists to sensory toolkits and fast-track pharmacy services, every step is designed to reduce stress and improve their experience. We have even introduced dedicated parking to make hospital visits easier for families. Our goal is to create a truly supportive and inclusive environment for every child and their family coming to Sidra Medicine for care”. The AFHI team at Sidra Medicine is led by Prof. Muhammad Waqar Azeem, Dr. Finza Latif, Dr. Alia Satti and Enas Hasab El Naby (Program Specialist). The initiative is based on the successful model developed by Boston Medical Center and adapted to Sidra Medicine’s needs through parent focus groups and staff feedback. Sidra Medicine is committed to supporting children with Autism ASD through specialized care. Our Developmental Pediatrics Clinic provides tailored assessments and interventions, guided by a multidisciplinary team. Additionally, our Child and Adolescent Mental Health Services (CAMHS) offer expert care for mental health conditions related to ASD, such as anxiety and depression, ensuring a comprehensive approach to the child’s overall well-being.
Sidra Medicine and İzmir Biomedicine and Genome Center (IBG) Sign MoU to Advance Pediatric Biomedical Research
Strengthening Collaboration in Genomics, Precision Medicine, and Translational Research 18 March 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has signed a Memorandum of Understanding (MoU) with the İzmir Biomedicine and Genome Center (IBG) to enhance collaboration in pediatric biomedical research. The agreement marks a significant milestone in fostering scientific research, innovation, and knowledge exchange between the two institutions. Dr. Iyabo Tinubu-Karch, Chief Executive Officer at Sidra Medicine, emphasized the significance of the partnership, stating: “The MoU with IBG is a major step in accelerating genomic discoveries for rare diseases. Our collaboration will focus on key areas including biobanking, genomics and multi-omics, bioinformatics, animal models of disease, and stem cell research. By working together, we aim to advance precision medicine and develop groundbreaking solutions for children with complex medical conditions.” Prof. Yılmaz, Director of IBG, said: “Partnering with Sidra Medicine, a globally recognized leader in pediatric healthcare and research, reinforces our commitment to advancing biomedical research. This collaboration will enable us to make meaningful strides in genomic and translational medicine, ultimately improving healthcare outcomes for children globally.” The partnership with IBG will also establish a framework for collaborative research projects, academic exchanges, and the sharing of expertise in key areas such as genomics, precision medicine, and translational research. By combining resources and knowledge, Sidra Medicine and IBG aim to address critical health challenges affecting children worldwide. Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine said: “Our agreement with IBG will also enable student exchanges and visiting scientist programs in both directions between Qatar and Turkey, as well as joint grant applications. Additionally, we will establish research cohorts with similar disorders across the MENAT region, helping us gain deeper insights into disease patterns and therapeutic interventions.” The agreement paves the way for future joint initiatives, including research collaborations, training programs, and knowledge-sharing efforts that will benefit both institutions and the broader scientific community.
WCM-Q students gain real-world exposure to Qatar’s healthcare system
Doha – March 18, 2025: Seventeen students from Weill Cornell Medicine-Qatar’s (WCM-Q) foundation and pre-medical programs participated in the 2024-2025 Pre-Medical Observership Program. The program provides students with valuable exposure to the healthcare system in Qatar and the daily practices of medical professionals. It allows them to explore the different medical specialties and career options available. The students spent two weeks of their winter break at affiliate hospitals Hamad Medical Corporation (HMC) and Sidra Medicine, where they shadowed physicians during their daily rounds in various clinics, including obstetrics and gynecology, surgery, internal medicine, emergency, and trauma. They also observed doctor-patient interactions and listened to doctors’ discussions of cases, diagnoses, and potential treatment plans. An additional observation opportunity was exclusively offered to foundation students, who spent a week at Sidra Medicine as part of their English language course. The 19 participating students combined classroom knowledge with observations of hands-on clinical experiences. Their observations focused on themes such as professionalism, teamwork, and professional identity, with each hospital visit centered around a specific theme. Commenting on his experience, pre-medical student Abdulaziz Al-Hardan said: “I gained valuable insights into patient care, clinical decision-making, and the realities of working in a fast-paced medical environment. Witnessing a variety of intricate medical situations helped me appreciate the value of teamwork, empathy, and communication in the medical field.” This passion for medicine was echoed by fellow students Noof Al-Malik and Jassim Al-Hail from the foundation program. Al-Malik said: “As a foundation student, it’s easy to lose sight of the end goal while being preoccupied with studying. This program reminded me of my love for the profession and reignited my determination to work hard to achieve my goals.” Al-Hail added: “The days that had the most significant impact on me were spent in the Trauma Intensive Care Unit (TICU). We not only observed the meticulous work of the doctors and their team of residents while treating patients suffering from brain trauma, but we also learned invaluable lessons about life, religion, and the art of medicine.” Upon completing the observership, the students submitted reflective essays and received certificates of participation. Dr. Rachid Bendriss, associate dean for foundation, student outreach and educational development programs, said: “We are committed to providing our foundation and pre-medical students with the opportunity to gain firsthand experience of what practicing physicians face during their daily rotations. We are extremely grateful to our affiliates for hosting these enriching experiences. Offering such opportunities early in a student’s academic journey helps set realistic expectations about the challenges and rewards of a medical career.”
High school students glimpse potential of a career in medicine at WCM-Q
Doha – March 16, 2025: Thirty-three high school students spent a week at Weill Cornell Medicine-Qatar (WCM-Q) discovering careers in medicine during the winter session of the Qatar Medical Explorer Program (QMEP). QMEP, an immersive enrichment program offered by WCM-Q’s Office of Student Outreach & Educational Development, provides a snapshot of life as a student at WCM-Q and detailed information about careers in medicine. The program is open to grade 10 and 11 students who have demonstrated academic excellence and a particular aptitude for the sciences and mathematics. During the weeklong program, the high school students took part in a carefully designed series of sessions designed to accurately reproduce the experiences of current WCM-Q students, with classes in biology, chemistry, anatomy, surgery, and research. There was also a presentation on the life of a practicing physician by a member of the WCM-Q faculty, plus opportunities to meet admissions officers, icebreaker sessions, and a mock admissions interview to help the students prepare for applying to college. The students also experienced practical classes in WCM-Q’s state-of-the-art Clinical Skills and Simulation Lab, before giving an oral presentation of a research project to their peers and WCM-Q faculty on the penultimate day of the program. On the evening of final day, the high school students were invited to join current WCM-Q students, faculty and staff for International Night, which celebrates the cultural diversity of the college community. Noha Saleh, director of premedical administration, student outreach and educational development, said: “QMEP is designed to give a very accurate impression to high school students of what life as a WCM-Q student is like and a clear understanding of what a career in science will entail. We are very happy to provide this chance for students to explore WCM-Q and we are certain that a great many of this year’s cohort left feeling very inspired about pursuing a career in medicine.” WCM-Q also runs QMEP sessions in the summer to provide more opportunities for students to explore careers in medicine. Entry to the program is based upon academic performance and nominations from high school counselors and teachers. Dr. Rachid Bendriss, professor of English as a second language, assistant professor of education in medicine, and associate dean for foundation, student outreach and educational development programs, said: “QMEP allows high school students with an interest in the sciences and good academic performance the chance to glimpse all that a career in medicine has to offer, as well as allowing them to explore WCM-Q’s state-of-the-art facilities and world-class levels of teaching. We hope that many of the inquisitive, intelligent and hardworking students who visited us during this session of QMEP will choose to join WCM-Q and go on to serve their communities as physicians, researchers, and educators.”
Sidra Medicine Study Identifies New Non-Invasive Method for Detecting Heart Disease Risk
Breakthrough Study Identifies Early Heart Disease Markers in Blood and Saliva 11 March 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has published a study in Scientific Reports, a journal from Nature Portfolio titled “Distinctive Blood and Salivary Proteomics Signatures in Qatari Individuals at High Risk for Cardiovascular Disease“. The study identifies protein markers that can help detect individuals at high risk of cardiovascular disease. These non-invasive methods contribute to advancing personalized healthcare and facilitating early diagnosis. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality globally, accounting for 29 percent1 of all deaths in Qatar, with risk factors like diabetes and hypertension driving the disease burden. In the broader Middle Eastern population, CVD accounts for 34 percent2 of deaths. The Sidra Medicine study offers promising insights into precision medicine, with the potential to transform strategies for managing and preventing CVD. Dr. Souhaila Al Khodor, Director of the Perinatal and Reproductive Health Division and Principal Investigator at the Laboratory of Microbiome and Biomarkers Discovery, said: “Our study is a step forward in advancing precision medicine for cardiovascular disease. We identified eight biomarkers for CVD-risk that appear in both blood and saliva, demonstrating that non-invasive saliva-based testing could serve as an alternative to traditional blood tests. This approach could significantly improve screening efforts, allowing for timely interventions and better management of modifiable risk factors such as diabetes, hypertension, and high cholesterol.” The research, conducted as part of the Microbiome and Biomarkers Discovery lab at Sidra Medicine, was led by Dr. Souhaila Al Khodor and Principal Investigators, Dr. Annalisa Terranegra and Dr. Jean Charles Grivel. The multidisciplinary team also included Dr. Ghada Yousif, Research Specialist and Staff Scientists – Dr. Selvasankar Murugesan, Dr. Mohamed Nadhir Djekidel and Dr. Giusy Gentilcore. Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine, said: “Qatar has built a world-class ecosystem for precision medicine, integrating genomic research, national biobanking, and targeted healthcare initiatives. With participants recruited through Qatar Biobank and funding from the Qatar National Research Fund, this study demonstrates how we can translate local genetic insights into innovative healthcare solutions that has global implications. By focusing on cardiovascular disease, which has a significant death rate in the region, we are addressing a critical health challenge and working to reduce its impact on the Qatari population.” Sidra Medicine continues to lead in advancing innovative healthcare solutions tailored to the needs of the Qatari population. Through cutting edge research, Qatar is driving breakthroughs in precision medicine, enhancing early diagnosis and risk management for cardiovascular disease. Click here to read the full study, which was awarded via Qatar National Research Fund’s Path to Precision Medicine 2-PPM2 grant under the Qatar Genome Program.
Sidra Medicine’s ENT Service Delivers Breakthrough in Airway Surgery
Qatar’s Only National Pediatric Tracheostomy Program Provides Expert and Innovative Care for Airway Conditions 4 March 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, is setting a new benchmark in pediatric healthcare with Qatar’s only national pediatric tracheostomy program. Supporting over 150 patients annually, the program has become a vital resource for families in Qatar, offering cutting-edge care and life-changing outcomes. In a recent success story, the Otolaryngology (ENT) team at Sidra Medicine successfully removed the tracheostomy tube of a 16-year-old patient. The patient experienced airway obstruction just above her vocal cords, which required the placement of a tracheostomy tube below the vocal cords to bypass the obstruction. Living with a breathing tube inserted through her neck was a life-altering condition, significantly limiting her as a high-functioning teenager. Despite undergoing multiple surgeries over the years to address the obstruction, previous attempts to resolve the issue and remove her tracheostomy had been unsuccessful. The team performed a unique combination of an epiglottoplasty and supraglottoplasty tailored specifically to her needs. The individualized approach, a first in Qatar, resolved the obstruction and allowed the patient to breathe normally through her nose for the first time in years. Dr. Taseer Feroze Din, an Attending Pediatric ENT Physician, who led the procedure on the young patient said: “This case highlights the strength of our airway surgical services and innovative approach to complex conditions. Our multidisciplinary team manages multiple new tracheostomies annually, cares for over 50 patients in long-term care, and supports over 100 patients in the community. Our team’s collaborative approach, which is harmonized by our nurse practitioner, Larkin Accinelli, has been pivotal in successes such as this. The aim of our program is to create a system that provides proactive management to prevent complications and optimize safe care for all our tracheostomized patients”. The patient’s mother shared her heartfelt gratitude: “Our daughter was born with a tightening in her throat, unable to breathe normally, and relied on a device to help her for the past 15 years. After five unsuccessful surgeries in the UK, Sidra Medicine here in Qatar, was the only place that could help her. We are deeply grateful to the doctors who provided exceptional care and checked on her tirelessly, even late into the night. It has been a long and painful journey since birth, but now after so many years, she can finally breathe on her own.” Dr. Faisal Abdelkader, Division Chief of Otolaryngology and Audiology at Sidra Medicine said: “Sidra Medicine’s tracheostomy program has doubled the number of successful tracheostomy removals in the past year, enabling children to lead more normal lives. The program has provided comprehensive care to local and international patients, including patients from Kuwait, Jordan, India, and Sri Lanka. We have become a trusted care partner for these families. I am equally proud of our efforts in presenting the development of the national tracheostomy program at international conferences in the USA, UAE and Tanzania, reinforcing our leadership in pediatric airway and tracheostomy care”. In addition to complex airway surgeries, the ENT service at Sidra Medicine provides a wide range of services, including complex sinus surgery, endoscopic ear surgery, pediatric sleep apnea treatment including the latest advances in adenoid and tonsil surgery, anterior skull base leak repair, endoscopic tear duct opening (DCR) and thyroid surgery. Using state-of-the-art equipment and a patient-centered approach, the team ensures exceptional care with optimal outcomes. For international inquiries about Sidra Medicine’s ENT services, please contact International.services@sidra.org. If you are based in Qatar, please call 40033333 for more information.
Minister of Public Health Launches “Sehatuha” Campaign Led by Weill Cornell Medicine-Qatar
Doha – February 26, 2025: His Excellency Mr Mansoor Bin Ebrahim Al Mahmoud, Minister of Public Health, inaugurated today the “Sehatuha” campaign, launched by Weill Cornell Medicine-Qatar (WCM-Q). This initiative marks a significant milestone in efforts to enhance women’s health, emphasizing the crucial role women play in society and the urgent need to prioritize their well-being. Dr Javaid Sheikh, Dean of WCM-Q, attended the launch ceremony alongside over 70 of the college’s alumni. The event featured the unveiling of the campaign’s visual identity, a film narrating the initiative’s journey and intended impact, as well as excerpts from web and podcast episodes presented by alumni. Additionally, Dr Bothina Al-Mulla and Dr Sulaiman Alshakhs, both graduates of WCM-Q and currently Practicing at Hamad Medical Corporation (HMC), shared their involvement in the campaign and underscored the importance of such initiatives. The Sehatuha campaign represents a dedicated effort to drive tangible change in line with WCM-Q’s mission to provide comprehensive healthcare solutions and foster community well-being. Inspired by the principle that “prevention is better than cure,” the campaign aims to raise awareness about health issues and preventive measures. Commenting on the initiative, His Excellency Mr Mansoor Bin Ebrahim Al Mahmoud highlighted the importance of Sehatuha in promoting women’s well-being. He stated, “This campaign supports our collective efforts under the National Health Strategy 2024-2030 to improve the health and well-being of the population, encouraging behavioral shifts towards greater health awareness and empowering individuals to take a proactive role in managing their health.” His Excellency further explained that women’s health had been a priority within the Second National Health Strategy, with intensified efforts to empower women and provide them with the necessary knowledge to lead healthier lives. His Excellency added, “Building on the significant achievements made, our new strategy continues to focus on improving health outcomes, with reproductive health as one of its key initiatives.” The Minister of Public Health also reaffirmed the Ministry’s commitment to supporting innovative health initiatives aimed at enhancing public health, commending the vital role played by WCM-Q in this domain. Additionally, His Excellency praised the support of Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development (QF), for the healthcare sector, as well as QF’s remarkable contributions to the advancement of Qatar’s healthcare system and the creation of a healthier society. In his welcome speech, Dr Javaid Sheikh praised Qatar’s visionary leadership and the inspiring contributions of female role models. He said, “Inspired by Her Highness Sheikha Moza bint Nasser, Sehatuha is more than just a health campaign—it’s a transformative movement that redefines healthcare and paves the way for a healthier, more empowered future for women. Through Sehatuha, we are creating a lifelong platform for women to learn, connect, and grow in their health journey, fostering a culture of self-care, community engagement, and a legacy that will positively impact future generations.” Dr Sheikh concluded by expressing his gratitude to Her Excellency Sheikha Hind bint Hamad Al Thani, Vice Chairperson and CEO of Qatar Foundation (QF), for her continued support of WCM-Q alumni and for empowering future generations of healthcare leaders. Sehatuha draws strength from its profound connection to the community, bridging gaps through WCM-Q’s alumni network. These healthcare leaders, who are rooted in the community and equipped with firsthand knowledge of its challenges, serve as key catalysts for change. The initiative was developed to support and raise awareness of women’s health issues, drawing on the experiences of alumni working across diverse specialties and healthcare institutions. Many WCM-Q alumni, with their deep roots in Qatar, either as nationals or long-term residents, are exceptionally positioned to champion and advance women’s healthcare education. Sehatuha addresses a woman’s entire lifecycle, from childhood and adolescence to motherhood and her golden years, highlighting health concerns specific to each stage. Utilizing state-of-the-art technology and digital platforms, it promotes physical health, mental and emotional well-being, healthy lifestyle habits, and self-care. Additionally, community engagement activities will be centered on these key themes. Beyond web and podcast episodes featuring WCM-Q alumni and experts, the Sehatuha campaign will host a series of workshops and lectures throughout the year. This dedicated approach provides practical knowledge and shared experiences to inspire and empower women in making informed choices about their health and well-being. By fostering a holistic and integrated health culture, Sehatuha aims to enhance women’s well-being, support a healthier society, and promote both physical and emotional health in Qatar and beyond.
Sidra Medicine and Rasmal Ventures Partner to Drive Digital Health Innovation in Qatar
Advancing Healthcare Through E-health Innovation and Startup Integration 25 February 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has signed a Memorandum of Understanding (MOU) with Rasmal Ventures, Qatar’s first venture capital firm. The strategic partnership, announced at the Web Summit Qatar 2025, marks a significant step in the hospital’s role in supporting and advancing digital health innovation in Qatar and beyond. Rasmal Ventures, with its extensive portfolio of global technology companies, will introduce Sidra Medicine to high-potential e-health startups and provide strategic support to incorporate innovative solutions into Sidra Medicine’s operations. In return, Sidra Medicine will contribute its clinical and research expertise to evaluate and refine the startups’ healthcare technologies, ensuring they are effective, scalable, and patient-focused. Moreover, the two organizations will develop entrepreneurship programs that encourage the development and growth of a Health-Tech sector for Qatar. Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine said: “This partnership highlights our commitment to establishing Sidra Medicine as a leading healthcare innovation hub in Qatar, in alignment with the Qatar National Vision 2030. By collaborating with Rasmal Ventures, we are building upon our current strengths in clinical care, genomics and cell and gene therapy, and taking a proactive approach to adopting innovative technologies and transforming Sidra Medicine into a living lab for entrepreneurial ventures from across Qatar and the world.” The MOU establishes a collaborative framework between the two entities to facilitate the exchange of expertise and best practices in e-health innovations. Through this partnership, Sidra Medicine and Rasmal Ventures aim to drive advancements in innovation, focusing on digital healthcare solutions such as patient-centric artificial intelligence (AI) technologies, telemedicine platforms, and wearable devices. Alexander Wiedmer, Co-Managing Partner at Rasmal Ventures said: “At Rasmal Ventures, we believe that innovation is key to transforming healthcare. Our partnership with Sidra Medicine represents a unique opportunity to bring the latest digital health technologies to the forefront, empowering Qatar’s healthcare system to deliver smarter, more efficient, and patient-centered care.” As part of the agreement, the two entities will host joint workshops, pilot studies, and discussions to validate the efficacy of emerging technologies and foster an open environment for innovation. This partnership positions Sidra Medicine as a driving force in healthcare innovation, creating valuable opportunities for biotech and healthtech leaders. It also underscores Sidra Medicine’s role as a premier destination for medical education and research, attracting innovators and nurturing the development of next-generation healthcare solutions.
Sidra Medicine Celebrates Graduates of Certificate in Leadership Program at Georgetown University in Qatar
Empowering the Next Generation of Healthcare Leaders 5 February 2025, Doha, Qatar – In a closing ceremony at Georgetown University in Qatar (GU-Q), Sidra Medicine celebrated the achievements of 14 middle and senior managers who completed the newly launched Strategic Leadership Development Certificate Program offered by Georgetown University. In her remarks, Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine, gave a background on why she initiated the program and the outcome she hoped to achieve, saying, “Our partnership with GU-Q has been instrumental in strengthening our investment in the growth of our national talent. I am confident that together, we will continue advancing Qatar’s vision of cultivating a highly skilled, innovative, and capable workforce—one that will drive the nation’s healthcare and broader development goals forward.” In her message to the graduates, Dr. Kelly Otter, Dean of Georgetown University School of Continuing Studies highlighted the importance of strategic leadership in building a better world, saying, “Your dedication and hard work will not only advance the goals of Sidra Medicine, but also will serve your communities well by providing holistic, patient-centric care. Your contributions will ensure that precision medicine is an accessible reality for many in the Gulf region.” Aysha Al-Kuwari, Director of the Talent Management Division at Sidra Medicine, added, “Strong leadership is the backbone of any successful healthcare institution. Through this collaboration with GU-Q, our managers have gained the skills to lead with confidence, adaptability, and a patient-first mindset—qualities that will drive both individual and institutional success at Sidra Medicine.” Launched in May 2024, the Strategic Leadership Certificate Program featured a distinguished faculty lineup, combining academic insights from Georgetown University’s Department of Health Systems Management with practical expertise from experienced healthcare industry executives. This tailored approach ensured that the 14 certificate holders are prepared to apply global healthcare insights and practical strategies to Sidra Medicine’s unique operational environment, leading to improved patient outcomes and enhanced organizational efficiency. Highlighting the Qatar campus’s strategic location and capacity to support this program, Andrew Henley, Chief Operating Officer of GU-Q, remarked, “As we celebrate our 20th Anniversary in Qatar, we are proud to support Georgetown’s School of Continuing Studies and leverage Georgetown’s global network of faculty expertise through GU-Q’s Office of Executive and Professional Education to help build Qatar’s knowledge economy and contribute to positive health, social, and economic outcomes for the region.”
Sidra Medicine Establishes Gene Therapy Center for Pediatric Rare Diseases
Bringing Life-changing Treatments for SMA and DMD Closer to Home 28 January 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has established a Gene Therapy Center to treat rare genetic diseases such as Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD). The announcement was made at Arab Health 2025 where Sidra Medicine will highlight its international patient service programs including flagship services such as gene therapy, reproductive medicine, the Heart Center and more. The Gene Therapy Center solidifies Sidra Medicine’s position as a regional leader in advanced care, attracting families from across the GCC and the Middle East and North Africa (MENA) region. Prof. Tawfeg Ben-Omran, Division Chief of Genetic and Genomic Medicine at Sidra Medicine, said: “In response to the overwhelming demand from neighbouring countries, the establishment of the Gene Therapy Center is a crucial step in meeting the needs of families seeking cutting-edge treatments for SMA and DMD. As a Qatari institution, our goal is to create a regional center of excellence, where children from across the Arab world can access advanced therapies without the need to travel long distances, bringing world-class care closer to home.” The Gene Therapy Center is designed to address the growing demand for innovative treatments for SMA and DMD. It plans to expand the service in the future for other rare and complex genetic diseases. Since the launch of its gene therapy program in 2022, Sidra Medicine has already provided groundbreaking therapies to 30 children with SMA and 15 children with DMD, attracting patients from 11 countries. Prof. Ibrahim Janahi, Acting Chief Medical Officer, Chair of Medical Education, and the Division Chief of Pulmonology said: “The availability of gene therapies for both SMA and DMD at Sidra Medicine represents a significant leap forward in the care of these rare genetic disorders. By offering these life-changing treatments, we are not only providing advanced medical solutions but also reducing the emotional and logistical challenges families face. Our International Patient Services team is dedicated to guiding families through every step of their journey, ensuring a smooth, and efficient experience throughout their time with us.” Leading the Way in Duchenne Muscular Dystrophy (DMD) Care DMD is the most common inherited muscle disorder, primarily affecting males, with symptoms typically appearing between the ages of two and three. As the disease progresses, it leads to severe muscle weakness, affecting mobility and, ultimately, respiratory and cardiac function. Globally, approximately 1 in 3,500 to 5,000 live male births are affected by the disorder. In the GCC region, specifically Saudi Arabia, studies have indicated a higher average age at diagnosis (7-8 years) compared to countries such as the United Kingdom – where the mean age is slightly above four years. This delay is attributed to factors such as limited awareness and lack of standardized diagnostic pathways. Recent advancements in gene therapy have provided new hope for DMD patients. Elevidys, developed by Roche Pharmaceuticals, is the first and only approved gene therapy for DMD. The treatment introduces a functional dystrophin gene to muscle and heart cells, slowing disease progression and improving muscle function. Sidra Medicine has become a key player in DMD care in the region. In June 2024, it made history by becoming the first hospital in Qatar and the fifth hospital worldwide to administer Elevidys to a DMD patient, Chris El Kik. This milestone marked the beginning of Sidra Medicine’s rapidly expanding DMD program. Building on this success, Sidra Medicine achieved another groundbreaking milestone in October 2024, becoming the first hospital outside the United States to administer Elevidys to children over the age of six. This highlights Sidra Medicine’s growing expertise and leadership in the care and treatment of DMD. Advancing Treatment for Spinal Muscular Atrophy (SMA) SMA is a rare genetic disorder that causes progressive muscle weakness and can be life-threatening, often resulting in the loss of vital motor functions such as sitting, crawling, or swallowing. In Saudi Arabia, the SMA carrier frequency is reported at 2.6%, which is slightly higher than the global average of 1.25% to 2%. The estimated birth incidence of SMA in Saudi Arabia is 32 per 100,000 live births, with approximately 2,265 individuals currently living with the condition. However, with advances in gene therapy, SMA is now treatable with Zolgensma, a cutting-edge treatment developed by Novartis that halts disease progression and improves outcomes. SMA is a rare genetic disorder that causes progressive muscle weakness and can be life-threatening, often resulting in the loss of vital motor functions such as sitting, crawling, or swallowing. In Saudi Arabia, the SMA carrier frequency is reported at 2.6%, which is slightly higher than the global average of 1.25% to 2%. The estimated birth incidence of SMA in Saudi Arabia is 32 per 100,000 live births, with approximately 2,265 individuals currently living with the condition. However, with advances in gene therapy, SMA is now treatable with Zolgensma, a cutting-edge treatment developed by Novartis that halts disease progression and improves outcomes. Sidra Medicine was selected as the lead treatment center for the MENA region by Novartis and has successfully administered Zolgensma to several children, including Malkha Rouhi, a young girl who received the therapy at the hospital. International Patient Services Each year, Sidra Medicine’s International Patient Services team works with families from outside Qatar who travel to receive specialized care at the hospital. Prof. Ziyad Hijazi, Medical Director of International Patient Services and Senior Attending Cardiologist said: “The diversity of our international patients at Sidra Medicine is a testament to our expertise. To date, the hospital has cared for over 1000 international patients from around the world, including Kuwait, Afghanistan, Iran, Iraq, Oman, Egypt, Turkey, Mozambique, Uganda, Kenya, South America, United Kingdom and more. We continue to be a trusted destination for those seeking the latest in pediatric cardiovascular care, neurosurgery, neurology, urology and gene therapy treatments including SMA and DMD.” If you are based overseas and want to inquire about our services including the Gene Therapy Center, please contact International.services@sidra.org. If you are based in Qatar, please